Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Parri, Alejandraca
• dc.contributor.author Fitó Colomer, Montserratca
• dc.contributor.author Torres, C. F.ca
• dc.contributor.author Muñoz-Aguayo, D.ca
• dc.contributor.author Schröder, Helmut, 1958-ca
• dc.contributor.author Cano, J. F.ca
• dc.contributor.author Vázquez, Luis Albertoca
• dc.contributor.author Reglero, G.ca
• dc.contributor.author Covas Planells, Maria Isabelca
• dc.date.accessioned 2018-01-18T08:53:03Z
• dc.date.available 2018-01-18T08:53:03Z
• dc.date.issued 2016
• dc.description.abstract Alkylglycerols (AKGs), isolated or present in shark liver oil have anti-inflammatory properties. Complement 3 (C3) and 4 (C4) participate in lipid metabolism and in obesity, contributing to the metabolic syndrome and to the low-grade inflammation associated with obesity. In a randomized, controlled, crossover study, 26 non-diabetes obese individuals were assigned two preparations with low (LAC, 10 mg AKGs) and high (HAC, 20 mg AKGs) AKG content. Intervention periods were of 3 weeks preceded by 2-week washout periods in which shark liver oil was avoided. Cholesterol, C3, C4, and vascular endothelial growth factor (VEGF) decreased in a linear trend (P < 0.01) from baseline (control) to LAC and HAC. Values after HAC were significantly lower (P < 0.05) versus both baseline and after LAC. No adverse effects were observed or reported. Data from this pilot study open a promising field for the study of the beneficial effects of AKGs on cardiovascular risk factors in obese individuals.
• dc.description.sponsorship This work has been done in the context of the University of Barcelona (UB), PhD Research Program in Dietetics and Nutrition (EEES H0502). It was supported by the Spanish Ministry of Science and Innovation/FEDER (European Regional Development Found-ERDF) financing the project AGL2006-02031, by Instituto de Salud Carlos III Miguel Servet’s contract (CP06/00100), and partially supported by the Agència de Gestió Ajuts Universitaris de Recerca 2009 SGR 1195. CIBEROBN and CIBERESP are initiatives of Instituto de Salud Carlos III, Madrid, Spain.
• dc.format.mimetype application/pdfca
• dc.identifier.citation Parri A, Fitó M, Torres CF, Muñoz-Aguayo D, Schröder H, Cano JF. Et al. Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals. Inflammopharmacology. 2016 Jun;24(2-3):127-31. DOI: 10.1007/s10787-016-0265-4
• dc.identifier.doi http://dx.doi.org/10.1007/s10787-016-0265-4
• dc.identifier.issn 0925-4692
• dc.identifier.uri http://hdl.handle.net/10230/33675
• dc.language.iso eng
• dc.publisher Elsevierca
• dc.relation.ispartof Inflammopharmacology. 2016 Jun;24(2-3):127-31
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PN/AGL2006-02031
• dc.rights © Elsevier http://dx.doi.org/10.1007/s10787-016-0265-4
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Alkylglycerols
• dc.subject.keyword Complement 3
• dc.subject.keyword Complement 4
• dc.subject.keyword Inflammation
• dc.subject.keyword Obesity
• dc.subject.keyword Vascular endothelial growth factor
• dc.subject.other Obesitat
• dc.title Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individualsca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion